ENERGIZE THE FIGHT.
FDA APPROVES TK2D THERAPY
The U.S. Food and Drug Administration (FDA) has approved UCB’s Kygevvi (doxecitine and doxribtimine) to treat the mitochondrial disease TK2d. “It’s hard to put into words what today’s decision means for patients living with TK2d,” said UMDF President and CEO Kristen Clifford. READ MORE >>
Our Mito Champions
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Need to Connect with Us?
Call the Support Line: (888) 900-6486
PRESS RELEASE: Leading Clinicians and Researchers Urge FDA to Reconsider Path Forward for DCA in Pyruvate Dehydrogenase Complex Deficiency
Leading advocacy groups and more than 80 scientific and medical leaders call on FDA to act urgently on DCA approval for PDCD, a rare and life-threatening mitochondrial disease WASHINGTON, D.C. — October 13, 2025 — In response to the recent Complete Response Letter...
READ THE LETTER: Leading Clinicians and Researchers Urge FDA to Reconsider Path Forward for DCA in Pyruvate Dehydrogenase Complex Deficiency
Click the Expand Button in the bottom right on the widget for a larger, full-screen view of the PDF.
October 2025 Newsletter: Celebrating an Approval, Therapeutic Pipeline News, FBXL4 Podcast, and More
Signup to receive the UMDF newsletter in your email monthly at umdf.org/newsletter-signup.